

|                         |  |
|-------------------------|--|
| <b>NCT ID</b>           | NCT05299840  |
| <b>Title</b>            | Impact of Using the Oncogramme(R) Device to Select the First Line of Treatment for Patients With Metastatic Colorectal Cancer  |
| <b>Phase</b>            | Not Applicable   |
| <b>Date Added</b>       | 2022-03-29   |
| <b>Location</b>         | France   |
| <b>Prior IO Allowed</b> | No   |
| <b>CRC-directed</b>     | Yes  |
| <b>Status</b>           | Recruiting   |
| <b>Drugs</b>            |  |
| <b>Tags</b>             | MSI-H/ MMRd, MSS/ MMRp   |
| <b>NCT ID</b>           | NCT05292417  |
| <b>Title</b>            | Radiotherapy in Combination With Sintilimab?GM-CSF and Fruquintinib in Patients With MSS mCRC  |
| <b>Phase</b>            | Phase 2  |
| <b>Date Added</b>       | 2022-03-23   |
| <b>Location</b>         | China  |
| <b>Prior IO Allowed</b> | No   |
| <b>CRC-directed</b>     | Yes  |
| <b>Status</b>           | Recruiting   |
| <b>Drugs</b>            | Fruquintinib, GM-CSF, Sintilimab   |
| <b>Tags</b>             | MSS/ MMRp  |
| <b>NCT ID</b>           | NCT05291156  |
| <b>Title</b>            | CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy  |
| <b>Phase</b>            | Phase 2  |
| <b>Date Added</b>       | 2022-03-22   |
| <b>Location</b>         | Italy  |
| <b>Prior IO Allowed</b> | Yes  |
| <b>CRC-directed</b>     | Yes  |
| <b>Status</b>           | Recruiting   |
| <b>Drugs</b>            | Avelumab, cetuximab  |
| <b>Tags</b>             | MSI-H/ MMRd, MSS/ MMRp   |
| <b>NCT ID</b>           | NCT05286814  |
| <b>Title</b>            | M9241 in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer or Intrahepatic Cholangiocarcinoma |
| <b>Phase</b>            | Phase 2  |
| <b>Date Added</b>       | 2022-03-18   |
| <b>Location</b>         | Maryland, United States  |
| <b>Prior IO Allowed</b> | No   |
| <b>CRC-directed</b>     | Yes  |
| <b>Status</b>           | Recruiting   |
| <b>Drugs</b>            |  |
| <b>Tags</b>             | MSS/ MMRp  |
| <b>NCT ID</b>           | NCT05277051  |
| <b>Title</b>            | First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors   |
| <b>Phase</b>            | Phase 1  |
| <b>Date Added</b>       | 2022-03-14   |

|                         |  |
|-------------------------|--|
| <b>Location</b>         | California, United States<br>North Carolina, United States<br>Oklahoma, United States<br>Pennsylvania, United States<br>Texas, United States<br>Utah, United States<br>Australia<br>Canada<br>China<br>France<br>Japan<br>South Korea<br>Spain<br>United Kingdom |
| <b>Prior IO Allowed</b> | Yes  |
| <b>CRC-directed</b>     | Yes  |
| <b>Status</b>           | Recruiting   |
| <b>Drugs</b>            | Dostarlimab, GSK4381562  |
| <b>Tags</b>             | MSI-H/ MMRd, MSS/ MMRp   |
| <b>NCT ID</b>           | NCT05243862  |
| <b>Title</b>            | Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer.  |
| <b>Phase</b>            | Phase 2  |
| <b>Date Added</b>       | 2022-02-17   |
| <b>Location</b>         | Arizona, United States<br>Florida, United States<br>Minnesota, United States   |
| <b>Prior IO Allowed</b> | No   |
| <b>CRC-directed</b>     | Yes  |
| <b>Status</b>           | Active, not recruiting   |
| <b>Drugs</b>            | Atezolizumab, PolyPEPI1018, Tecentriq  |
| <b>Tags</b>             | MSS/ MMRp  |
| <b>NCT ID</b>           | NCT05239741  |
| <b>Title</b>            | Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)   |
| <b>Phase</b>            | Phase 3  |
| <b>Date Added</b>       | 2022-02-15   |
| <b>Location</b>         | China  |
| <b>Prior IO Allowed</b> | No   |
| <b>CRC-directed</b>     | Yes  |
| <b>Status</b>           | Recruiting   |
| <b>Drugs</b>            | 5-Fluorouracil, Irinotecan, Leucovorin, oxaliplatin  |
| <b>Tags</b>             | MSI-H/ MMRd  |
| <b>NCT ID</b>           | NCT05217446  |
| <b>Title</b>            | A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer ( SEAMARK )   |
| <b>Phase</b>            | Phase 2  |
| <b>Date Added</b>       | 2022-02-01   |

|                         |   |
|-------------------------|---|
| <b>Location</b>         | Arizona, United States<br>California, United States<br>Florida, United States<br>Tennessee, United States<br>Texas, United States<br>Australia<br>Belgium<br>Canada<br>Czechia<br>Denmark<br>France<br>Germany<br>Italy<br>Netherlands<br>Norway<br>Poland<br>Slovakia<br>Spain<br>United Kingdom |
| <b>Prior IO Allowed</b> | No  |
| <b>CRC-directed</b>     | Yes   |
| <b>Status</b>           | Active, not recruiting  |
| <b>Drugs</b>            | encorafenib, Braftovi, Erbitux, Keytruda  |
| <b>Tags</b>             | MSI-H/ MMRd   |
| <b>NCT ID</b>           | NCT05215574   |
| <b>Title</b>            | Study of NGM831 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors   |
| <b>Phase</b>            | Phase 1   |
| <b>Date Added</b>       | 2022-01-31  |
| <b>Location</b>         | Arizona, United States<br>California, United States<br>Florida, United States<br>Michigan, United States<br>New York, United States<br>Oklahoma, United States<br>Texas, United States  |
| <b>Prior IO Allowed</b> | Yes   |
| <b>CRC-directed</b>     | Yes   |
| <b>Status</b>           | Active, not recruiting  |
| <b>Drugs</b>            | NGM831, NGM831 plus pembrolizumab   |
| <b>Tags</b>             | MSI-H/ MMRd, MSS/ MMRp  |
| <b>NCT ID</b>           | NCT05213195   |
| <b>Title</b>            | NKG2D CAR-NK Cell Therapy in Patients With Refractory Metastatic Colorectal Cancer  |
| <b>Phase</b>            | Phase 1   |
| <b>Date Added</b>       | 2022-01-28  |
| <b>Location</b>         | China   |
| <b>Prior IO Allowed</b> | Yes   |
| <b>CRC-directed</b>     | Yes   |
| <b>Status</b>           | Recruiting  |
| <b>Drugs</b>            | NKG2D CAR-NK  |
| <b>Tags</b>             | MSI-H/ MMRd, MSS/ MMRp  |